Recent developments and current controversies in depression

Klaus P Ebmeier, Claire Donaghey, J Douglas Steele

In this review of the last 5 years' developments in research into depression we focus on recent advances and current controversies. We cover epidemiology and basic science as well as the treatment of depression in adults in all its forms. Depression in childhood and adolescence, as well as in old age has been covered in recent Seminars in *The Lancet*. Depression in adulthood remains a very common and under-treated condition, resulting in a high degree of disability. Increasingly detailed knowledge about impairment of information processing in depression is being supplemented by quantitative studies of the brain processes underlying these impairments. Most patients improve with present treatments. The mechanisms of action of antidepressants are not fully understood; the hypothesis that reversing hippocampal cell loss in depression may be their active principle is a fascinating new development. Moral panic about the claim that antidepressant serotonin reuptake inhibitors cause patients to commit suicide and become addicted to their medication may have disconcerted the public and members of the medical profession. We will try to describe the considerable effort that has gone into collecting evidence to enlighten this debate.

Compared with other medical diagnoses, depression is very common. It occurs twice as frequently in women as in men, can begin at any age, but has its average age of onset in the mid-20s.[1] Lifetime prevalence estimates for major depressive disorder (panel) in the community range from 15% to 17% (95% CI),[1] 12-month prevalence from 6% to 7% (US national comorbidity replication; n=9090).[2,3]

Major depressive disorder impairs the ability to function, leading to role impairment in well over 50 % of patients.[2] Role impairment is likely to be a direct corollary of depressed mood.[4,5] Effective treatment is therefore of the essence. Unfortunately, only 46–57% (95% CI) of the 12-month cases in the USA were receiving health care treatment for major depressive disorder, and only 18–25% were adequately treated.[2] In a European community survey (n=5993), 25–38% of men and 21–30% of women interviewed and classified as having major depressive disorder used any health services in the past 12 months for their depression. This percentage rose to only 35–49% of those with severe major depressive disorder.[6] Any discussion of the epidemic rise in prescriptions of antidepressants together with popular scepticism towards antidepressant treatments has to be considered against this background (figure 1). Depression is especially common in many non-psychiatric medical settings, such as inpatients wards, in chronically ill patients and during the recovery from acute medical illness.[7]

A crucial aspect of the epidemiology of major depression is the increased mortality associated with this condition. A recent meta-analysis of 25 studies with 1·3–16 years' follow-up of over 100 000 individuals reported an overall relative risk of dying between 1·58 and 2·07 (95% CI) compared with people who are not depressed.[8] The relative risk in subclinical depression was not substantially smaller than in clinical depression. The analysis did not examine

potential confounders, such as chronic illness or lifestyle. The mechanism of increased mortality is therefore not clear. A major contribution to increased mortality in depression will come from the risk of suicide in this patient group. Traditionally, lifetime risk (ie, proportionate mortality: the percentage of the dead who died by suicide during follow-up) is reported between 15% and 19%.[9,10] This figure is likely to be inflated, especially if the period of follow-up, typically after an acute episode in hospital, carries a higher risk of suicide than periods further removed from the index episode.[11]

Another modifying factor is the diagnostic system: early versions of the Diagnostic and Statistical Manual of Mental Disorders (DSM), for example, drew the boundaries of depression much narrower than DSM III or IV, which include many milder forms of the illness. A recent review[11] took account of the treatment setting of patients and identified a clear hierarchy of risks, with estimates of lifetime prevalence of suicide being highest in suicidal inpatients (8·6%), lower in other inpatients (4%), and lowest amongst outpatients with affective disorder (2·2%). Even with these revised figures the risk of suicide rises over background levels from four-fold in depressed outpatients to 16-fold in patients with affective disorders admitted because of suicidal risk.[11]

A sixth of people in the community will have major depressive disorder during their lifetime. Only between a quarter and half of patients will be in contact with the

Search strategy and selection criteria

We searched MEDLINE, and for some topics EMBASE and PsychInfo, initially limiting the search to systematic reviews and meta-analyses, then if necessary to controlled studies. Recent national guidelines and reports were also reviewed.

health services for their depression. In half the cases, the illness is incapacitating, leading to role impairment at work or at home. The risk of premature death is increased, in part because of a greater risk of suicide.

Causes and associations

Genetics and pharmacogenetics

There is no doubt that genetic factors have an important role in the aetiology of depression. Heritability has been estimated from twin studies as 31–42%, with a substantial contribution of environmental effects unique to individuals (including measurement error) of 58–67%.[12] Depression with recurrent episodes and possibly early onset may be associated with greater familial aggregation.[12]

Traditional genetic linkage studies and candidate gene methods have been used with fairly limited success in major depression.[13] Genetic models of aetiology generally assume a large number of genes with relatively small contributions to liability. Advances in high-throughput genotyping and microarray techniques have made it more feasible to identify genes with small effect sizes.[13] Of special clinical interest are those studies that are based on pathophysiological notions (candidate genes), and in particular those that examine the probability of patients to respond to particular treatments.

Brain-derived neurotrophic factor may have a central role in the effectiveness of antidepressants, but there is no firm evidence of an association of its alleles with major depressive disorder.[14–16] Monoamine oxidase A is involved in the metabolism of catecholamines and is the target of one group of antidepressants, the monoamine oxidase inhibitors. Certain monoamine oxidase A gene promoter polymorphisms are found in subgroups of patients with major depression; they are by no means specific to depression, but also occur in patients with anxiety.[17,18] The catechol-O-methyltrans-ferase (another catecholamine metabolising enzyme) Val108/158Met polymorphism has been intensively investigated in psychotic disorders, but has also been associated with treatment response to mirtazepine, but not paroxetine, in major depression.[19] Human tryptophan hydroxylase-2 (hTPH2) is involved in the synthesis of serotonin. The theory that it is the rate-limiting step of serotonin synthesis is supported by the occasional success of the augmentation of anti-depressants with tryptophan.[20] A single nucleotide polymorphism in its gene with roughly 80% loss of function is associated with major depression, but not with bipolar illness.[21]

The most frequently examined candidate gene codes for the serotonin transporter, which is the drug target of serotonin reuptake inhibitors, such as fluoxetine. A 44-bp insertion or deletion results in a long (l) and a short (s) variant of this gene; the s-variant is associated with a two-fold decreased expression and transport activity in vitro. Individuals in an epidemiological sample with one or two copies of the short allele of the serotonin transporter promoter polymorphism showed more depressive symptoms, diagnosable depression, and tendency to commit suicide in relation to stressful life events than individuals homozygous for the long allele.[22] Unfortunately, two subsequent twin studies were not concordant in lending support to this result.[23,24] The importance of the s-variant of the gene for stress susceptibility is supported by an increased amygdala response to stimuli of threat during a functional MRI study and an increased prefrontal response to an error processing task in healthy volunteers.[25,26] The association of serotonin transporter alleles with hippocampal size is more complex and seems to be related to age of onset.[27,28] Patients with two alleles of the l-variant generally show a better clinical response to serotonin reuptake inhibitors in studies of mainly white patients.[29,30] The other serotonin transporter polymorphism described has a variable number of tandem repeats (9, 10, and 12 copies)

***

Panel: ICD-10 criteria for depression[3]

Depressive episode

At least two weeks of: depressed mood, loss of interest and enjoyment, reduced energy, increased fatiguability, diminished activity, reduced concentration and attention, reduced self esteem and self confidence, ideas of guilt and unworthiness, bleak view of the future, ideas or acts of self-harm, disturbed sleep, diminished appetite

Mild depression

Two of depressed mood, loss of interest and enjoyment, reduced energy, and two others

Patient will not cease to function completely

Moderate depression

Two of depressed mood, loss of interest and enjoyment, reduced energy, and at least three others, some at marked intensity

Considerable difficulty functioning

Severe depression

Two of depressed mood, loss of interest and enjoyment, reduced energy, and at least four others, some of severe intensity, plus considerable distress and agitation, or psychomotor retardation; sometimes with psychotic symptoms, such as hallucinations or delusions

Dysthymia

Depression of mood which is never or only very rarely severe enough to fulfil the criteria for recurrent depressive disorder, mild or moderate severity

Very long-standing

Usually begins in early adult life, lasts at least for several years

Low mood varies little from day to day, is often unresponsive to circumstances, yet may show a characteristic diurnal variation. Anhedonia is a core feature of all depressive illnesses. Anxiety symptoms and weight loss are common. If episodes of mania or hypomania occur, the illness is called bipolar affective disorder.

located in intron 2 of the gene. There may be a better response rate in 12/12, as opposed to 10/12 patients, but this improved rate has only been shown in Asian studies.[29,30] A recent search for pharmacokinetic effects of *CYP2D6* and *CYP2C19* alleles suggested that for 14 of 20 investigated antidepressants, at least a doubling of the dose would be needed in extensive metabolisers compared with poor metabolisers. This variation in effects does strengthen the argument for antidepressant plasma monitoring in depression resistant to treatment.[29] Although promising and fascinating, the prospective practical application of such genetic and pharmacogenetic information is still some time away.

Heritability of depression has been estimated to range from 30–40%. Because of its pattern of inheritance, but also because of heterogeneity of clinical samples, no genes of major effect have been identified. A multitude of genes with small effects are likely to be identified, which will be related to certain aspects of genetic vulnerability to depression and will work alongside or interact with environmental factors.

Changes in cognitive performance

Most people now accept that major depressive disorder is associated with cognitive impairment. Episodic memory seems to be the main aspect of cognitive functioning that is vulnerable to the negative effects of depression.[31–33] Temporal lobe lesions typically disrupt episodic memory. Since hippocampal atrophy has been shown in patients with major depressive disorder,[34] impaired episodic memory function in depression might be associated with dysfunction of the hippocampus.[35,36]

Factors that can affect episodic memory in depressive disorders are depression subtype, severity, and age. Although this topic has been widely researched, findings have been equivocal. In one study, major depression and mixed anxiety-depressive disorder were associated with greater impairments than dysthymia, whereas in minor depression cognitive performance was unaffected.[33] In another study,[37] the number of depressive episodes was associated with verbal memory deficits, which could be an indication of sensitisation to the effect of depression with progressive cerebral dysfunction and anatomical changes.[35,38]

Further, psychomotor slowing and executive functioning—namely mental flexibility and attention—are impaired in people with depressive disorders.[33,36,38–40] Equally, updating of content—ie, working memory, set-shifting, and inhibition processes—are impaired in depressed patients compared with controls.[40] Psycho-motor symptoms have been commonly associated with depressive episodes.[41] Since there is no objective evidence that psychomotor retardation is present in dysthymic patients this sign could be used to


***Figure 1*: Prescription cost analysis data for new antidepressants**
Figure produced from data from the UK prescription pricing authority, for all age groups 1999–2003. (UK Department of Health, Statistics Division 1E, Prescription Cost Analysis system.)

differentiate between dysthymia and major depressive disorder.[42]

The presence of cognitive abnormalities in some depressed patients is generally accepted now. From a practical point of view, they may interfere with activities of daily life, such as driving or working, but also with attempts to recruit cognitive processes for therapeutic purposes. The detailed analysis of cognitive data processing and its effect on mood and other dimensions of depressive symptoms have just started.

In vivo anatomical and functional brain changes

Most people now accept that hippocampal size measured by MRI is reduced in patients with unipolar major depressive disorder.[43,44] There is some discussion, however, about the clinical correlates of this change. Duration of illness, repeated episodes, treatment resistance (all partly overlapping) and previous abuse might be associated with hippocampal change.[35,43–45] Hippocampal atrophy has also been described in victims of abuse and of battle-induced post traumatic stress disorder.[46–49] Findings of animal studies suggest that increased glucocorticoid levels lead to impaired neurogenesis, excitotoxic damage or reduced levels of key neurotrophins in the hippocampus.[50,51] Of particular interest to the clinician, however, is that antidepressants can reverse these changes and that blocking hippocampal neurogenesis by irradiation can prevent the action of antidepressants in behavioural animal models of depression.[52–55]

Figure 2: Forest plot of controlled trials of transcranial magnetic stimulation in depression
Information based on Burt and colleagues (2002),[140] and subsequently published papers.[141-168] Effect sizes (Cohen's d) were computed from changes in Hamilton or Montgomery-Asberg depression scores at beginning and end of treatment (2–3 weeks); when SD of difference scores were not available, SD of raw scores were used following Dunlap's suggestion.[169] Studies show sufficient heterogeneity (Q [non-combinability for d+]=60·82 (df=27), p=0·0002) to suggest that systematic modifying factors are at work and pooled effect size is not a reliable estimate. DL pooled effect size=0·680035 (95% CI=0·430108–0·929962).

Furthermore, hippocampal atrophy might be associated with cognitive impairment, in particular for episodic memory.[35,56] In the absence of larger longitudinal studies of depressed patients, whether the changes observed in hippocampus in cross-sectional studies are in fact the result of depression and stress (as postulated above), or whether they are the cause of certain clinical characteristics of the illness in the patients affected—such as treatment resistance or frequent relapses—remains to be resolved.[35]

Functional MRI (fMRI) is the method of choice to examine brain-behaviour relations. Anterior cingulate, orbitofrontal cortex, dorsolateral cortex, striatum, and medial temporal lobe have repeatedly been reported as abnormal in functional and structural imaging studies of depressed patients.[57–61] In healthy human beings and animals, the ventromedial prefrontal region is associated with emotional experience,[62,63] and the dorsolateral region with cognitive and motor function.[64,65] Findings of neuroimaging studies of mood disorder tend to show abnormally increased activity in emotion-related brain regions and underactivity in cognition-related regions.[59–61,66] Neurosurgery for treatment-resistant mood disorder (a very rarely used procedure) has long targeted the ventromedial prefrontal region, excluding the dorsolateral region, since dorsolateral lesions cause cognitive deficits. Recently, ventromedial prefrontal overactivity was reported to predict response to a neurosurgical procedure for treatment-resistant mood disorder.[67] In the following section we discuss fMRI studies of depressive illness reported in the past few years. All the studies explore possible mechanisms of abnormal function.

As discussed above, major depressive disorder is characterised not only by depressed mood, but also by a substantial impairment of cognitive function. Lateral orbitofrontal cortex is activated in healthy individuals undertaking a verbal fluency task. In depressive illness, impaired verbal fluency is associated with attenuated activation in this brain region.[68] During a spatial working memory task done with gradually increasing task difficulty (n-back task), reduction in task accuracy in depressed patients was related to abnormally increased ventromedial prefrontal activity.[69] This relation is consistent with an emotional gating model explaining cognitive performance in depression.[70] Although not specifically described in these studies, increased activity of the ventromedial emotion-related prefrontal region is often associated with underactivity of the cognitive processing region, and vice versa.[71]

Many studies of depressive illness have focused on affective response, though such paradigms always include some cognitive component. Decreased rostro-medial prefrontal and hippocampal activation, and increased temporal lobe activity in depression were shown in a cognitive picture-caption paradigm to generate an affective response.[72] These changes suggest that in depressive illness the decrease in rostro-medial prefrontal and hippocampal activation was associated with impairment of positive affect, and the increase in temporal lobe activity with enhanced negative affect. This anatomical dissociation between positive and negative affective response might be related to abnormality in behavioural reward and inhibition systems proposed on the basis of many studies in animals[62,73] and early deep-brain electrical recording in humans.[74]

A robust finding in neuropsychological studies of depressive illness is a bias towards processing mood-congruent information. By contrast with healthy

people, depressed patients show a facilitation of response to stimuli with a negative emotional tone. Studies of abnormal emotional bias have the advantage that they explicitly link mood and cognition in a way that can be related to cognitive-behavioural theories of depressive illness and treatment. In an emotional go/no-go task, patients had attenuated neural responses to emotional targets in the subgenual anterior cingulate and posterior orbitofrontal cortices, and raised responses to sad targets in the rostral anterior cingulate and medial prefrontal cortex.[75] Elliott and colleagues[75] concluded that the orbito-medial prefrontal region has a distinct role in mediating mood-congruent information processing biases in depressive illness. In a study of the neural response to facial expression, a systematic alteration in neuronal activity was associated with such bias in regions that included the parahippocampal gyrus and amygdala.[76] Surguladze and colleagues[76] suggested that this bias could be linked to the negative cognitions and social dysfunction that arise in depressive illness. Depressed individuals characteristically engage in long-term elaborative cognitive processing of emotional information. Using a mathematical, artificial neural network model of attentional biases in depressive illness, Siegle and colleagues[77] made a formal prediction of brain response to positive, negative, and neutral stimuli. They tested these predictions with two emotional processing tasks, and reported that, as predicted, depressed individuals had abnormally sustained amygdala activity in response to affectively negative words, which was related to self-reported rumination.[77]

Formal mathematical models are increasingly used to predict brain activity.[78] Models of emotional learning have been established from extensive work in animals and more recent replicated imaging work on healthy people. Emotional learning involves adaptation and is associated with neural predictive error signals. Mathematical models can describe both the signals and behaviour. The hypothesis that depressive illness is a disorder of emotional learning associated with abnormal error signals was tested with a gambling task.[78] Consistent with the prediction, patients had abnormally increased error signals in various limbic brain regions. The results are consistent with cognitive-behavioural theories of depressive illness, neural plasticity theories of antidepressant action, and successful neurosurgical interventions.[78,79]

The studies[68,69,71,72,75–78] discussed in the previous paragraphs all investigate impaired cognitive function, cognitive-emotional bias and abnormal neural activity in depressive illness. Postulated mechanisms leading to depressive symptoms have been investigated and a focus of the work has been to link clinical presentation with underlying neural activity. Further work in testing these hypotheses in relation to treatment for depressive


***Figure 3*: Deep brain stimulation and lesion sites in the ventromedial prefrontal lobe**
CS=coronal section location, ICLS=internal capsulotomy[187] and stimulation location,[188] SACLS=subgenual and medial orbitofrontal lesion[190] and stimulation[186] location, NAS=shell of nucleus accumbens stimulation location.[189] All interventions were bilateral with the exception of the NAS.[189] For completeness, the supragenual anterior cingulotomy[187] lesion site (ACL) is also shown.

illness should have priority, since these are the mechanisms of most clinical interest.

Recent electrophysiological studies of depressive illness might have direct links to quantitative models of brain function. Of particular interest is the error-related negativity (ERN) signal, which is a negative deflection in averaged electroencephalogram (EEG) recordings that peaks about 100 ms after participants make an incorrect response in speeded time-response tasks.[80,81] The onset of this potential precedes the erroneous response, suggesting that the cognitive system knew about the error as it was being made.[81] This signal is sometimes referred to as the response ERN, to distinguish it from another signal, the feedback ERN, which peaks later at 250 ms, and is a response to actual feedback information that the behaviour was incorrect. The neural generators of these signals are in the anterior cingulate,[82,83] a structure repeatedly reported as abnormal in functional and structural neuroimaging studies of depressive illness.[60] The ERN has been suggested to be not only an indication of the registering of an error or conflict, but also of the affective consequences of expectancy violations—in particular aversive emotions including anxiety.[84]

Various experimental studies in healthy participants appear to lend support to these theories. For example, people with high trait anxiety have increased ERN,[80,85] and acute alcohol intoxication decreases the ERN.[86] In clinical studies, patients with obsessive-compulsive

disorder who were tested with a speeded reaction-time task showed an ERN with substantially raised amplitude.[87] Gehring and colleagues[87] linked this to abnormal behavioural learning mechanisms and aversive emotional experience. In a more recent study, patients with major depressive disorder undertook a signal detection task with continuous feedback that signalled monetary reward. Compared with controls, patients showed a reduced ERN, and the investigators suggested that this reduction indicated underactivity of central reward pathways.[88] The same group then replicated this finding with a go/no-go task.[89] Since the ERN could arise as a consequence of phasic decreases in activity of the predictive error signals discussed previously,[90] these findings accord with the idea that depressive illness is a disorder of emotional learning.[79]

The link between ERN and aversive emotion lends support to the independent proposal of a direct theoretical link between predictive error signals and polarity and intensity of normal emotion.[91] Although the terms emotion or affect and mood are often used interchangeably in clinical practice, mood is traditionally not emotion, but a sustained predisposition or bias to emotion, expressed as affect, along a single dimension from elation to depression.[92] For a particular emotive stimulus, the abnormal bias associated with a depressive illness should therefore be associated with a corresponding bias of predictive error signals[79] or ERN. Future studies of mood disorder should attempt to clearly distinguish between positive and negative errors of response and feedback, rewarded versus aversive learning paradigms, and unmedicated, acutely medicated, and chronically medicated states. Allelic variation of the serotonergic transporter modulates the ERN.[26] Of equal or more interest are investigations into the effects of acute and chronic administration of antidepressant medication on the ERN and predictive error signals, and the contrast between treatment-responsive and treatment-resistant patients.

The general understanding of depression has evolved from a vague notion of mood and emotion to a differentiated understanding about how emotional and motivational changes interact with information processing in patients' brains. This progress has helped to localise the anatomical structures and neuronal systems underlying depressive symptoms, and at the same time has provided us with a fuller understanding of the real obstacles that depressed patients struggle against.

Treatments
Efficacy of psychological treatments
Cognitive behavioural therapy is a psychological treatment which was first formalised in the late 1970s.[93] The main premise is that depressive symptoms arise from dysfunctional beliefs and thought processes as a result of early learning experiences. These beliefs lie dormant for a number of years, but are activated by a situation or an event that has a specific meaning for the individual.[94] Schema focused work tries to directly address this premise; by definition, a schema is a cognitive structure embedded in long-term memory that has been acquired over a lifetime of learning. At best, this information has been stored to allow a person to perceive and understand. For many patients though, identifying and challenging negative automatic thoughts is the main focus of treatment.

Several studies have shown the advantage of cognitive-behavioural therapy over other psychological therapies and placebo and equivalence to treatment as usual (ie, anti-depressant medication) in the treatment of unipolar depression.[95,96] In a primary care setting, cognitive-behavioural therapy and non-directive counselling were both significantly more effective than usual family doctor care at 4 months' follow-up. However, there was no longer a significant difference between these three treatments at 12 months.[97] Not all research has lent support to the use of cognitive-behavioural therapy over other therapies in the treatment of depression. A study of patients treated with fluoxetine dose increase alone or in combination with cognitive-behavioural therapy examined the frequency of residual depressive symptoms during the continuation phase.[98] The combination of cognitive-behavioural therapy with fluoxetine had equal efficacy to fluoxetine alone. In a further study, pharmacotherapy had an advantage over cognitive-behavioural therapy, which tended to be larger in patients with chronic depression.[99] Research looking at the advantages of combining antidepressants with psychotherapy has been equivocal.[100]

Evidence that cognitive-behavioural therapy reduces rates of relapse and recurrence in unipolar depression has accumulated.[101,102] Although the evidence from these studies is strong, the duration of this preventive effect after the discontinuation of cognitive-behavioural therapy is unclear. In one study the researchers concluded that the effect of cognitive-behavioural therapy in reduction of relapse and recurrence persists for many years, with the effects being lost fully between 3 and 4 years after cessation of the treatment.[103] In a review[104] of the long-term effectiveness of cognitive-behavioural therapy in major depressive disorder Hensley and colleagues concluded that the evidence lends support to the long-term effectiveness of CBT over tricyclic antidepressants alone. This conclusion, however, should be treated tentatively since only five trials between 1981 and 1992 were included. Thus, we need further studies into the prevention of recurrence with cognitive-behavioural therapy.

Klerman and Wiesmann developed interpersonal therapy in the early 1980s,[105] which is based on the premise that depression occurs in a social and

interpersonal context. Interpersonal therapy focuses mainly on present rather than past relationships and on interpersonal rather than intra-psychic processes.

Even though the content of interpersonal therapy differs from that of behavioural and cognitive therapies, treatment outcomes for depression are broadly similar.[106] The recently published National (English and Welsh) Institute of Clinical Excellence (NICE) guidelines on the treatment of depression agree with this finding by stating that there is insufficient evidence to determine whether there is a clinically significant difference between psychotherapies such as interpersonal therapy and cognitive-behavioural therapy on reducing depressive symptoms. Furthermore, they suggest that there is some evidence implying that there is no clinically significant difference between interpersonal therapy and antidepressants on reducing depressive symptoms as measured by the Hamilton rating scale for depression.[107]

There is a dearth of systematic reviews and randomised controlled trials (RCTs) on interpersonal therapy in the recurrence and relapse prevention of unipolar depression. However, a sequential treatment strategy in women with recurrent major depression was investigated to look at the efficacy of adding anti-depressant medication (imipramine) to interpersonal therapy in those who did not remit with such treatment alone.[108] The study found that in the absence of remission, adding antidepressant pharmacotherapy to interpersonal therapy could be highly effective, enabling a number of individuals to achieve a full remission from depressive symptoms.[108] A similar study was conducted with dysthymic patients in a primary care setting.[109] The findings were similar to the previous study since the researchers showed that interpersonal therapy plus antidepressant medication (sertraline) was effective in reducing symptoms. However, there was no significant difference between sertraline alone and sertraline plus interpersonal therapy, and these two treatment conditions were more effective than interpersonal therapy alone at 6 months' follow-up. This was also the case at 2 years' follow-up.

Additionally, there has been some research on maintenance interpersonal therapy. Maintenance interpersonal therapy employs the same techniques as the standard version, but its main goal is the prevention of recurrence and it is seen more as a long term rather than an acute intervention.[110] The little research that has been compiled on maintenance treatment has concentrated on depression in later life. The findings may be transferable to those suffering with depression between the ages of 18 years to 65 years (mid-life depression). Reynolds and colleagues[111] compared medication (nortriptyline) and interpersonal therapy as maintenance therapies for recurrent depression in older adults. They noted that for the

treatment of recurrent depression, medication or IPT were better than placebo and clinic visits in prevention of recurrence. Furthermore, the combination of nortriptyline with IPT was the optimum treatment condition.

Problem solving therapy is a cognitive-behavioural approach. The main goal of the treatment is to alter the problematic nature of the current situation, the patients' reaction to such situations, or to achieve both these goals.[112] It works on the premise that by teaching problem solving skills one is able to improve their ability to cope with life stresses.[113] Problem solving was originally delineated by D'Zurilla and Goldfried[114] and was later revised by D'Zurilla and others.[115] Support for problem solving therapy and the treatment of depression has been fairly strong. In a primary care based study, problem solving therapy was an effective treatment for patients with major depression and the improvement in mood was maintained over a 52 week follow-up.[116] Furthermore, the combination of this treatment with antidepressant medication (paroxetine or fluvoxamine) was no more effective than either treatment alone. In a community study of the prevention of depression, the participants were randomly assigned to either the problem solving therapy or group psychoeducation.[117] Outcomes were positive for both treatment groups at 6 months' follow-up. However, patients that were assigned to problem solving were less likely to report depressive symptoms.

In a study of remission rates and the correlates of remission of minor depression with problem solving therapy in adult and older adult patients, this treatment as well as paroxetine showed greater effectiveness over placebo plus clinical management.[118] Women, younger patients, and those with lower baseline severity of depression were more likely to achieve remission, independent of whether they had been treated with paroxetine, problem solving therapy, or placebo.[119] Furthermore, problem solving therapy seemed less suitable for patients whose minor depression had arisen as a result of more chronic life and health problems.[119]

Thus, problem solving therapy does have fairly strong support for the treatment of depressive disorders. There is, however, a need for further research, since that done has focused mainly on either dysthymia or minor depression and has been done in a primary-care setting. To further enhance the effectiveness of this treatment it would be worthwhile comparing it with other psychological therapies such as cognitive-behavioural therapy and interpersonal therapy.

Although all three treatments seem to be psychotherapies of choice when treating depression, there are other psychotherapies such as behaviour therapy, psychodynamic psychotherapy, and non-directive counselling, to name but a few. However, there are few randomised controlled trials to endorse

the efficacy and effectiveness of these treatments in primary care and research settings. An interesting meta-analysis looked at the effects of cognitive-behavioural therapy versus other psychotherapies in the treatment of depression.[120] Psychotherapies were divided into bona fide—ie, those that have been developed with the specific intention of treating depression—and non-bona fide versus CBT. There was no advantage of cognitive-behavioural therapy for depression, and all bona fide psychological treatments were equally effective.[119]

Psychotherapies are now generally recommended as treatment of milder depression or as an adjunct to antidepressant drugs in more severe illness. For obvious reasons their evidence base is thinner than that for antidepressant drugs. There is no evidence for a better rationale of any particular psychotherapy, since several approaches with different underlying assumptions seem to be equally efficacious.

Medication in depression

In a review of antidepressant treatments, NICE went well beyond guidelines published by the American Psychiatric Association[121] by coming to the conclusion that antidepressants are not recommended for the initial treatment of mild depression, because the risk-benefit ratio is poor. Instead it advocates psychosocial treatment or some form of psychotherapy.[107] In moderate to severe depression, antidepressants are recommended, though preferably in combination with psychotherapy.[107] Apart from a small evidence base, there are some practical problems with the implementation of these recommendations, since mood-related cognitive impairment and poor motivation could make psychotherapeutic treatment of depressed patients difficult. Very little evidence exists for the treatment of depression in the context of alcohol and drug dependence, although this is a frequent and important comorbidity. The lack of availability of adequately trained psychotherapists is another obstacle.

The NICE recommendations are representative of a trend in public perception, which seems to run ahead of contemporary clinical practice: Although data on effectiveness have been the prime criterion for deciding on treatment recommendations in the past, risks of side-effects and patients' choice are increasingly taking their place next to treatment effectiveness (see also prescription data for paroxetine in figure 1).[122–124] This change in emphasis explains the NICE recommendation for mild depression, as well as the institution of working groups, and enquiries on the treatment of depression in children and adults by the US Food and Drug Administration, the US Congress,[125] and the UK Medicines and Healthcare products Regulatory Agency.[126] Antidepressant drugs of choice are, in the first instance, serotonin reuptake inhibitors,

such as fluoxetine, paroxetine, fluvoxamine, citalopram, and sertraline.[107] The main risks that have been associated with serotonin reuptake inhibitors are treatment-emergent suicidal behaviour and withdrawal symptoms, especially in children and adolescents.[126] Since side-effects are not the primary outcome measure in most drug trials, their recording and reporting tends to be poor. Some potential drug effects, such as suicide, are so rare that drug trials are of necessity underpowered to find any effects. The absence of comprehensive and reliable evidence for risks,[126] perceived industrial interests of clinicians,[127,128] as well as publication bias, which is well known to any author of systematic reviews, have in some quarters eroded public faith in the drug treatment of depression and its regulation.[124,129,130]

The most serious risk associated with depression is increased mortality, especially that due to suicide. Experimental studies of suicide risk or prevention per se are virtually impossible, because of the very low period prevalence of suicide during clinical studies, even in depressed patients. Indirect methods, such as meta-analyses and epidemiological studies provide some lower level evidence.[131,132] Proxy measures of suicide, such as suicidal behaviour, deliberate self harm, or reported suicidal thoughts are more frequent and can be examined instead, as long as they are treated as only one of many risk factors for actual suicide.[133,134] Any intervention that is associated with greater frequency of suicidal thoughts is therefore not necessarily linked to an actual increase in suicides, because suicidal thoughts might in any one case not be the decisive risk factor.[126,133,134] Clinical lore suggests that suicidal risk increases early during treatment, because recovery takes place in degrees, with energy and motivation for example improving before mood. Although there is some evidence of increased suicidal behaviour in the early stages of treatment,[135] this does not seem to be linked to a particular drug or class of antidepressant.[126,133,136] The relative risk of finding serotonin reuptake inhibitors at post mortem after self-poisoning is actually smaller than for other antidepressants, presumably because of their lower toxicity in overdose.[137] Post-hoc studies of patients treated in clinical practice have confirmed that there is no increased risk of suicidal behaviour with serotonin reuptake inhibitors compared with other drugs, despite a potential bias amongst clinicians to prescribe serotonin reuptake inhibitors to suicidal patients, rather than the more toxic alternatives.[135,136,138]

The controversy about serotonin reuptake inhibitor-withdrawal symptoms seems mainly to be about semantics. There is no doubt that withdrawal symptoms occur after stopping SRIs and other antidepressants. The neologism discontinuation symptoms essentially means the same as withdrawal symptoms, without having any association with

addiction. Withdrawal symptoms are, of course, a common, but by no means a sufficient criterion to define drug dependence or addiction.[126] Withdrawal symptoms occur particularly, but not exclusively, on withdrawal from paroxetine and venlafaxine. An unexpected and rare symptom is the experience of electric shock sensations, often localised to the head and limbs. With increasing numbers of pregnant mothers going through pregnancy on serotonin reuptake inhibitors, the occasional occurrence of withdrawal in neonates needs to be considered.[139] There is no evidence that antidepressants cause actual addiction.[126]

Drug treatments remain the mainstay of antidepressant therapy. Recent moral panics about suicidal effects and dependence-inducing potential of antidepressants have tilted the balance of publicly perceived risk against them, but both their effectiveness and their ready availability make them the likely choice for most patients.

Physical treatments in depression

Transcranial magnetic stimulation has recently received much publicity, both as an interesting method to investigate neuronal function in vivo in humans and as a potential treatment method to supplement or even to replace drug treatment and electroconvulsive treatment in depression.[140] It has great potential as a non-invasive investigative method, especially if combined with imaging methods. Transcranial magnetic stimulation is able to disturb neuronal activity in a way that allows for the examination of causality, rather than generating associations, as most imaging methods do. Combined with neuroimaging, the spatial distribution of such stimulated neuronal networks can be mapped. After initial enthusiasm about its treatment potential, the current assessment is more sober. The forest plot of controlled trials in depression indicates a secular trend with more recent trials showing smaller effect sizes (figure 2).[140–169]

This pattern might be partly due to the choice of treatment-resistant and drug treated patients, but also to inadequate blinding to placebo. The most commonly used placebo condition is to tilt the coil by 45° away from the scalp, a method that may result in some cortical stimulation or in a different perception of surface stimulation of scalp muscles and skin by the patient. Most studies have focused on high frequency (10–20 Hz) stimulation of the left or low frequency (1 Hz) stimulation of the right dorsolateral prefrontal cortex. There is no good evidence that these are the only coil positions and stimulation frequencies with antidepressant effects, although several neuroimaging studies during such stimulation protocols have shown changes in brain activity and neurotransmitter binding that seem relevant to depressive symptoms.[170–172] The development of new stimulation protocols, such as θ

burst stimulation,[173,174] could lead to more effective treatment protocols, but in the meantime transcranial magnetic stimulation remains an experimental treatment modality.

A potential, but rare side-effect of transcranial magnetic stimulation, especially at higher frequencies and intensities, is the induction of seizures.[175] Because of the actual difficulty of inducing seizures reliably with transcranial magnetic stimulation, attempts to replace electric induction of seizures for electroconvulsive therapy (ECT) with this treatment are fairly recent.[176–179] A major advantage of magnetic over electric seizure induction is that the magnetic field can penetrate scalp and skull without hindrance, whereas the electric current used for ECT is impeded by the resistance of surface structures and the brain, requiring the stimulation of various extracranial and intracranial structures before a seizure can be induced. Magnetic seizure therapy is, therefore, likely to lead to less unnecessary stimulation resulting in fewer side-effects such as memory impairment.[176]

Electroconvulsive therapy

Despite public and professional misgivings, ECT remains the most effective treatment for depression, especially if it presents with psychotic symptoms, such as delusions and hallucinations.[180,181] Apart from the risk of general anaesthetic, the main objection to ECT has been its liability to cause memory impairment. Research on cognitive functioning after ECT has been far from comprehensive and is complicated by the improvement of cognition due to the alleviation of depressive symptoms. A recent robust study examined the effects of ECT on episodic memory and noted that the anterograde amnesic effects of ECT were greater for knowledge about the world—ie, impersonal memory, than for autobiographical memory—ie, personal memory.[182] In a systematic review and meta-analysis[180] the UK ECT Review Group stated that data relating to cognitive functioning after ECT were not complete, but the tentative conclusion could be drawn that cognitive impairment consisted mostly of temporary anterograde and retrograde amnesia.[180] Furthermore, the method of ECT used in the treatment of depression was linked to the degree of cognitive impairment produced. For example, bilateral ECT produces greater impairment than unilateral ECT, and higher energy treatment produces greater impairment than lower energy.[183] The effects of ECT are short-lived so patients are likely to require follow-on pharmacological therapy.[184] Further research into the long-term cognitive effects of ECT is recommended as there is a dearth of randomised controlled trials researching this area.[180]

The role of neurosurgery in the management of patients highly resistant to treatment and its invasive nature make future randomised controlled studies

unlikely. Vagal nerve stimulation has been proposed as a treatment in drug-resistant and ECT-resistant depressed patients, but the evidence for its effectiveness is as yet inconclusive.[185] Deep brain stimulation as a currently experimental treatment might offer an intervention similar to neurosurgery, which is both reversible and amenable to within-participant placebo control. Six patients with severe refractory depressive disorder, who had failed to respond to antidepressant, psychotherapeutic, and electroconvulsive therapies were treated in an open study, in which electrodes were implanted in the white matter tracts immediately lateral to the subgenual anterior cingulate.[186] Striking and sustained remission of depression was reported in four of the six patients. Furthermore, PET images showed a pronounced reduction in locally abnormally increased subgenual cerebral metabolism, as well as changes in downstream cortical and limbic sites. The authors[186] concluded that disrupting focal pathological activity in the subgenual region using deep brain stimulation could effectively reverse symptoms in depression that is otherwise resistant to treatment.

Other recent studies have reported the results of deep brain stimulation for refractory obsessive-compulsive and anxiety disorders. Based on studies of internal capsulotomy for these disorders,[187] four patients with treatment refractory severe obsessive-compulsive disorder were reported in an open study. The patients had electrodes implanted in the anterior limbs of the internal capsule.[188] This stimulation had beneficial effects in three patients, with one having an especially striking result. For this one patient, the investigators then did a double-blind trial with video assessment and six independent assessors. The findings of the more rigorous double-blind assessment supported the conclusions of the initial less detailed open study assessment; during deep brain stimulation the patient had a pronounced increase in ratings of social contact, communication, flow of ideas, assertiveness and mobility, a decrease in doubt, and no change in sustained attention.[188]

On the basis of this and other work, an open study investigated treatment of refractory obsessive-compulsive disorder and anxiety disorders with deep brain stimulation of the anatomically adjacent shell of the nucleus accumbens.[189] A good reduction in symptom severity was reported in three of four patients. Additionally, PET images of one patient during stimulation showed a change in brain metabolism as a result of the stimulation. Figure 3[187–189] shows the locations of these procedures.

Two distinct issues remain to be determined from such work: treatment effectiveness and treatment mechanism. Determination of treatment effectiveness should take no account of theories of mechanism, but should instead use the accepted methods of evidence-based medicine.[191] The need for evidence-based medicine in assessing neurosurgery for mental disorders has long been recognised. However, there are considerable practical difficulties in implementing evidence-based medicine methods in a treatment of last resort, for which very few patients, even worldwide, are judged suitable. There are no prospective randomised double-blind placebo-controlled trials of any procedure, and none is likely.[192] In the case of deep brain stimulation however, the publication of a double-blind trial[188] in a single patient is encouraging for future studies of stimulation effectiveness.

There are two main theories of treatment mechanism that are not mutually contradictory. Both theories take account of the apparent similarity of clinical response to lesioning and stimulation of the same brain regions. The first theory relates to evidence from work in animals and man for regional specialisation of brain function. In the prefrontal cortex, the ventromedial region seems to be the substrate for normal and pathological emotional experience.[60,62,63,65] Damage to this region in previously healthy people has been reported to diminish emotional experience.[193,194] Deliberate damage to the ventromedial prefrontal region in patients with intractable mood disorder and anxiety might therefore diminish distressing symptoms. Deep brain stimulation at sufficiently high intensities and frequencies has a blocking effect on the stimulated area, mimicking the effects of tissue lesioning.[189] The second theory addresses the issue of whether similar therapeutic effects might occur with limited lesions and weaker stimulation, and has direct links with contemporary stochastic theories of normal brain function. Baev[195] and colleagues have proposed a mechanism of action for partial lesioning and deep brain stimulation in Parkinson's disease. An analogous theory has been proposed for mood and anxiety disorders.[79] Such theories are testable using neuroimaging in people, studies on animals, and quantitative modelling.[79]

Of the physical treatments only ECT is in regular clinical use. Transcranial magnetic stimulation, magnetic seizure therapy and vagal nerve stimulation offer hope of treatment that is potentially less invasive or liable to generate memory impairment. Neurosurgery for mental disorders is reserved for very few highly treatment-resistant patients, whereas deep brain stimulation may be able to emulate some of its effects with the opportunity for blind and randomised assessment, as well as reversibility of its effects.

Summary

Depression is not only a very common, incapacitating, and occasionally lethal illness that deserves our full attention, but also spans a wide range of severity and

requires a large choice of treatments. It is common in non-psychiatric medical settings and crucially affects presentation with physical illness and recovery from such illness. All effective treatments for this condition, which is by its very nature associated with the most profound suffering, have to be welcomed.

References
1   American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
2   Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). *JAMA* 2003; **289:** 3095–105.
3   WHO. The ICD-10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines (CDDG). Geneva: World Health Organization, 1992.
4   Spijker J, Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA. Functional disability and depression in the general population. Results from the Netherlands mental health survey and incidence study (NEMESIS). *Acta Psychiatr Scand* 2004; **110:** 208–14.
5   Ormel J, Oldehinkel AJ, Nolen WA, Vollebergh W. Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects. *Arch Gen Psychiatry* 2004; **61:** 387–92.
6   Hamalainen J, Isometsa E, Laukkala T, et al. Use of health services for major depressive episode in Finland. *J Affect Disord* 2004; **79:** 105–12.
7   Aben I, Verhey F, Strik J, Lousberg R, Lodder J, Honig A. A comparative study into the one year cumulative incidence of depression after stroke and myocardial infarction. *J Neurol Neurosurg Psychiatry* 2003; **74:** 581–85.
8   Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. *J Affect Disord* 2002; **72:** 227–36.
9   Guze SB, Robins E. Suicide and primary affective disorders. *Br J Psychiatry* 1970; **117:** 437–38.
10 Goodwin FK, Jamison KR. Suicide. In: Goodwin FK, Jamison KR, eds. Manic-depressive illness. New York: Oxford University Press, 1990: 227–44.
11 Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. *Am J Psychiatry* 2000; **157:** 1925–32.
12 Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. *Am J Psychiatry* 2000; **157:** 1552–62.
13 Hong CJ, Tsai SJ. The genomic approaches to major depression. *Curr Pharmacogenom* 2003; **1:** 67–74.
14 Schumacher J, Jamra RA, Becker T, et al. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. *Biol Psychiatry* 2005; **58:** 307–14.
15 Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. *Am J Med Genet B Neuropsychiatr Genet* 2003; **123:** 19–22.
16 Hong CJ, Huo SJ, Yen FC, Tung CL, Pan GM, Tsai SJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. *Neuropsychobiology* 2003; **48:** 186–89.
17 Schulze TG, Muller DJ, Krauss H, et al. Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. *Am J Med Genet* 2000; **96:** 801–03.
18 Du L, Bakish D, Ravindran A, Hrdina PD. MAO-A gene polymorphisms are associated with major depression and sleep disturbance in males. *Neuroreport* 2004; **15:** 2097–101.
19 Szegedi A, Rujescu D, Tadic A, et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. *Pharmacogenomics J* 2005; **5:** 49–53.
20 Nelson JC. Augmentation strategies in depression 2000. *J Clin Psychiatry* 2000; **61** (suppl 2): 13–19.
21 Zhang X, Gainetdinov RR, Beaulieu JM, et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. *Neuron* 2005; **45:** 11–16.
22 Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. *Science* 2003; **301:** 386–89.
23 Gillespie NA, Whitfield JB, Williams B, Heath AC, Martin NG. The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression. *Psychol Med* 2005; **35:** 101–11.
24 Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B. The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. *Arch Gen Psychiatry* 2005; **62:** 529–35.
25 Hariri AR, Mattay VS, Tessitore A, et al. Serotonin transporter genetic variation and the response of the human amygdala. *Science* 2002; **297 :** 400–03.
26 Fallgatter AJ, Herrmann MJ, Roemmler J, et al. Allelic variation of serotonin transporter function modulates the brain electrical response for error processing. *Neuropsychopharmacology* 2004; **29:** 1506–11.
27 Frodl T, Meisenzahl EM, Zill P, et al. Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. *Arch Gen Psychiatry* 2004; **61:** 177–83.
28 Taylor WD, Steffens DC, Payne ME, et al. Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. *Arch Gen Psychiatry* 2005; **62:** 537–44.
29 Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. *Mol Psychiatry* 2004; **9:** 442–73.
30 Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. *Mol Psychiatry* 2004; **9:** 433–41.
31 Ilsley JE, Moffoot AP, O'Carroll RE. An analysis of memory dysfunction in major depression. *J Affect Disord* 1995; **35:** 01–09.
32 Sweeney JA, Kmiec JA, Kupfer DJ. Neuropsychologic impairments in bipolar and unipolar mood disorders on the CANTAB neurocognitive battery. *Biol Psychiatry* 2000; **48:** 674–84.
33 Airaksinen E, Larsson M, Lundberg I, Forsell Y. Cognitive functions in depressive disorders: evidence from a population-based study. *Psychol Med* 2004; **34:** 83–91.
34 Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. *Proc Natl Acad Sci USA* 1996; **93:** 3908–13.
35 Shah PJ, Ebmeier KP, Glabus MF, Goodwin GM. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. *Br J Psychiatry* 1998; **172:** 527–32.
36 Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: possible implications for functional neuropathology. *Br J Psychiatry* 2001; **178:** 200–06.
37 Fossati P, Harvey PO, Le Bastard G, Ergis AM, Jouvent R, Allilaire JF. Verbal memory performance of patients with a first depressive episode and patients with unipolar and bipolar recurrent depression. *J Psychiatr Res* 2004; **38:** 137–44.
38 Fossati P, Coyette F, Ergis AM, Allilaire JF. Influence of age and executive functioning on verbal memory of inpatients with depression. *J Affect Disord* 2002; **68:** 261–71.
39 Porter RJ, Gallagher P, Thompson JM, Young AH. Neurocognitive impairment in drug-free patients with major depressive disorder. *Br J Psychiatry* 2003; **182:** 214–20.

40 Harvey PO, Le Bastard G, Pochon JB, et al. Executive functions and updating of the contents of working memory in unipolar depression. *J Psychiatr Res* 2004; **38**: 567–76.

41 Sobin C, Sackeim HA. Psychomotor symptoms of depression. *Am J Psychiatry* 1997; **154**: 04–17.

42 Pier MP, Hulstijn W, Sabbe BG. No psychomotor slowing in fine motor tasks in dysthymia. *J Affect Disord* 2004; **83**: 109–20.

43 Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. *Am J Psychiatry* 2004; **161**: 1957–66.

44 Campbell S, Marriott M, Nahmias C, MacQueen GM. Lower hippocampal volume in patients suffering from depression: a meta-analysis. *Am J Psychiatry* 2004; **161**: 598–607.

45 Shah PJ, Glabus MF, Goodwin GM, Ebmeier KP. Chronic, treatment-resistant depression and right fronto-striatal atrophy. *Br J Psychiatry* 2002; **180**: 434–40.

46 Bremner JD, Randall P, Scott TM, et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. *Am J Psychiatry* 1995; **152**: 973–81.

47 Bremner JD, Randall P, Vermetten E, et al. Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse—a preliminary report. *Biol Psychiatry* 1997; **41**: 23–32.

48 Gurvits TV, Shenton ME, Hokama H, et al. Magnetic resonance imaging study of hippocampal volume in chronic, combat-related posttraumatic stress disorder. *Biol Psychiatry* 1996; **40**: 1091–99.

49 Stein MB, Koverola C, Hanna C, Torchia MG, McClarty B. Hippocampal volume in women victimized by childhood sexual abuse. *Psychol Med* 1997; **27**: 951–59.

50 Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. *J Psychiatry Neurosci* 2004; **29**: 417–26.

51 Fuchs E, Czeh B, Kole MH, Michaelis T, Lucassen PJ. Alterations of neuroplasticity in depression: the hippocampus and beyond. *Eur Neuropsychopharmacol* 2004; **14** (suppl 5): S481–90.

52 Fuchs E, Czeh B, Flugge G. Examining novel concepts of the pathophysiology of depression in the chronic psychosocial stress paradigm in tree shrews. *Behav Pharmacol* 2004; **15** : 315–25.

53 McEwen BS, Chattarji S. Molecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine. *Eur Neuropsychopharmacol* 2004; **14** (suppl 5)**:** S497–502.

54 Duman RS. Depression: a case of neuronal life and death? *Biol Psychiatry* 2004; **56**: 140–45.

55 Reid IC, Stewart CA. How antidepressants work: new perspectives on the pathophysiology of depressive disorder. *Br J Psychiatry* 2001; **178**: 299–303.

56 Squire LR. Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. *Psychol Rev* 1992; **99**: 195–231.

57 Ebert D, Ebmeier KP. The role of the cingulate gyrus in depression: from functional anatomy to neurochemistry. *Biol Psychiatry* 1996; **39**: 1044–50.

58 Drevets WC. Neuroimaging studies of mood disorders. *Biol Psychiatry* 2000; **48**: 813–29.

59 Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. In: Frackowiak RS, Jones T, eds. Imaging neuroscience: clinical frontiers for diagnosis and management. Oxford: Oxford University Press, 2003: 193–207.

60 Ebmeier KP, Kronhaus D. Brain imaging and mood disorders. In: D'haenen H, den Boer JA, Willner P, eds. Biological psychiatry. London: John Wiley and Sons, 2002.

61 Steele JD, Lawrie SM. Neuroimaging. In: Johnstone EC, Lawrie SM, eds. Edinburgh companion to psychiatric studies. Edinburgh: Churchill Livingstone, 2004.

62 Rolls ET. The brain and emotion. Oxford: Oxford University Press, 1999.

63 Steele JD, Lawrie SM. Segregation of cognitive and emotional function in the prefrontal cortex: a stereotactic meta-analysis. *Neuroimage* 2004; **21**: 868–75.

64 Vogt BA, Finch DM, Olson CR. Functional heterogeneity in cingulate cortex: the anterior executive and posterior evaluative regions. *Cereb Cortex* 1992; **2**: 435–43.

65 Fuster JM. The prefrontal cortex. New York: Lippincott-Raven, 1997.

66 Drevets WC. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. In: Uylings HBM, Van Eden CG, De Bruin JPC, Feenstra MGP, Pennartz CMA, eds. Progress in brain research. London: Elsevier Science, 2000.

67 Dougherty DD, Weiss AP, Cosgrove GR, et al. Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for treatment of major depression. *J Neurosurg* 2003; **99**: 1010–17.

68 Okada G, Okamoto Y, Morinobu S, Yamawaki S, Yokota N. Attenuated left prefrontal activation during a verbal fluency task in patients with depression. *Neuropsychobiology* 2003; **47**: 21–26.

69 Rose EJ, Simonotto E, Ebmeier KP. Limbic over-activity in depression during preserved performance on the n-back task. *Neuroimage* 2006; **29**: 203–15.

70 Pochon JB, Levy R, Fossati P, et al. The neural system that bridges reward and cognition in humans: an fMRI study. *Proc Natl Acad Sci USA* 2002; **99**: 5669–74.

71 Drevets WC, Raichle ME. Reciprocal suppression of regional cerebral blood flow during emotional versus higher cognitive processes: implications for interactions between emotion and cognition. *Cogn Emotion* 1998; **12**: 353–85.

72 Kumari V, Mitterschiffthaler MT, Teasdale JD, et al. Neural abnormalities during cognitive generation of affect in treatment-resistant depression. *Biol Psychiatry* 2003; **54**: 777–91.

73 Gray JA, McNaughton N. The neuropsychology of anxiety: an enquiry into the functions of the septo-hippocampal system. 2nd edn. Oxford: Oxford University Press, 2000.

74 Heath RG. Correlation of brain function with emotional behavior. *Biol Psychiatry* 1976; **11**: 463–80.

75 Elliott R, Rubinsztein JS, Sahakian BJ, Dolan RJ. The neural basis of mood-congruent processing biases in depression. *Arch Gen Psychiatry* 2002; **59**: 597–604.

76 Surguladze S, Brammer MJ, Keedwell P, et al. A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder. *Biol Psychiatry* 2005; **57**: 201–09.

77 Siegle GJ, Steinhauer SR, Thase ME, Stenger VA, Carter CS. Can't shake that feeling: event-related fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals. *Biol Psychiatry* 2002; **51**: 693–707.

78 Steele JD, Meyer M, Ebmeier KP. Neural predictive error signal correlates with depressive illness severity in a game paradigm. *Neuroimage* 2004; **23**: 269–80.

79 Steele JD. Depressive illness and emotional learning. *Curr Med Imaging Rev* 2005; **1**: 157–176.

80 Luu P, Collins P, Tucker DM. Mood, personality, and self-monitoring: negative affect and emotionality in relation to frontal lobe mechanisms of error monitoring. *J Exp Psychol Gen* 2000; **129**: 43–60.

81 Holroyd CB, Nieuwenhuis S, Mars RB, Coles MG. Anterior cingulate cortex, selection for action, and error processing. In: Posner MI, ed. Cognitive neuroscience of attention. London: Guildford Press, 2004.

82 Holroyd CB, Nieuwenhuis S, Yeung N, et al. Dorsal anterior cingulate cortex shows fMRI response to internal and external error signals. *Nat Neurosci* 2004; **7**: 497–78.

83 Luu P, Tucker DM, Derryberry D, Reed M, Poulsen C. Electrophysiological responses to errors and feedback in the process of action regulation. *Psychol Sci* 2003; **14**: 47–53.

84 Luu P, Pederson SM. The anterior cingulate cortex, regulating actions in context. In: Posner MI, ed. Cognitive neuroscience of attention. London: Guildford Press, 2004.

85 Hajcak G, McDonald N, Simons RF. Anxiety and error-related brain activity. *Biol Psychol* 2003; **64**: 77–90.

86 Holroyd CB, Yeung N. Alcohol and error processing. *Trends Neurosci* 2003; **26**: 402–04.

87 Gehring WJ, Himle J, Nisenson LG. Action-monitoring dysfunction in obsessive-compulsive disorder. *Psychol Sci* 2000; **11**: 1–6.

88 Ruchsow M, Herrnberger B, Wiesend C, Gron G, Spitzer M, Kiefer M. The effect of erroneous responses on response monitoring in patients with major depressive disorder: a study with event-related potentials. *Psychophysiology* 2004; **41:** 833–40.

89 Ruchsow M, Herrnberger B, Beschoner P, Gron G, Spitzer M, Kiefer M. Error processing in major depressive disorder: evidence from event-related potentials. *J Psychiatr Res* 2005; published online May 6. DOI:10.1016/j.jpsychires.2005.02.002

90 Holroyd CB, Coles MG. The neural basis of human error processing: reinforcement learning, dopamine, and the error-related negativity. *Psychol Rev* 2002; **109:** 679–709.

91 Daw ND, Kakade S, Dayan P. Opponent interactions between serotonin and dopamine. *Neural Netw* 2002; **15:** 603–16.

92 Owens DC, McKenna PJ, Davenport R. Clinical assessment: interviewing and examination. In: Johnstone EC, Owens DC, Lawrie SM, Sharpe M, Freeman CPL, eds. Companion to psychiatric studies. Edinburgh: Churchill Livingstone, 2004.

93 Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive therapy of depression: a treatment manual. New York: Guilford Press, 1979.

94 Scott J. Cognitive therapy for depression. *Br Med Bull* 2001; **57:** 101–13.

95 Thase ME, Friedman ES, Berman SR, et al. Is cognitive behavior therapy just a 'nonspecific' intervention for depression? A retrospective comparison of consecutive cohorts treated with cognitive behavior therapy or supportive counseling and pill placebo. *J Affect Disord* 2000; **57:** 63–71.

96 Gloaguen V, Cottraux J, Cucherat M, Blackburn IM. A meta-analysis of the effects of cognitive therapy in depressed patients. *J Affect Disord* 1998; **49:** 59–72.

97 King M, Sibbald B, Ward E, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. *Health Technol Assess* 2000; **4:** 01-83.

98 Perlis RH, Nierenberg AA, Alpert JE, et al. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. *J Clin Psychopharmacol* 2002; **22:** 474–80.

99 Thase ME, Friedman ES, Fasiczka AL, et al. Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants. *J Clin Psychiatry* 2000; **61:** 466–72.

100 de Jonghe F, Hendricksen M, van Aalst G, et al. Psychotherapy alone and combined with pharmacotherapy in the treatment of depression. *Br J Psychiatry* 2004; **185:** 37–45.

101 Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. *Arch Gen Psychiatry* 1999; **56:** 829–35.

102 Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. *J Consult Clin Psychol* 2000; **68:** 615–23.

103 Paykel ES, Scott J, Cornwall PL, et al. Duration of relapse prevention after cognitive therapy in residual depression: follow-up of controlled trial. *Psychol Med* 2005; **35:** 59–68.

104 Hensley PL, Nadiga D, Uhlenhuth EH. Long-term effectiveness of cognitive therapy in major depressive disorder. *Depress Anxiety* 2004; **20:** 1–7.

105 Klerman GL, Weismann NM, Rounsaville BJ, Chevron ES. Interpersonal psychotherapy of depression. New York: Basic Books, 1984.

106 Barkham M, Hardy GE. Counselling and interpersonal therapies for depression: towards securing an evidence-base. *Br Med Bull* 2001; **57:** 115–32.

107 NICE. Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: National Institute for Clinical Excellence, 2004.

108 Frank E, Grochocinski VJ, Spanier CA, et al. Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression. *J Clin Psychiatry* 2000; **61:** 51–57.

109 Browne G, Steiner M, Roberts J, et al. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. *J Affect Disord* 2002; **68:** 317–30.

110 Frank E, Thase ME. Natural history and preventative treatment of recurrent mood disorders. *Annu Rev Med* 1999; **50:** 453–68.

111 Reynolds CF 3rd, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. *JAMA* 1999; **281:** 39–45.

112 Nezu AM. Problem solving and behavior therapy revisited. *Behaviour Therapy* 2004; **35:** 1–33.

113 Nezu AM, Nezu CM. Problem solving therapy. *J Psychother Integr* 2001; **11:** 187–205.

114 D'Zurilla TJ, Goldfried MR. Problem solving and behavior modification. *J Abnorm Psychol* 1971;**78**(1):107–26.

115 D'Zurilla TJ, Chang EC, Nottingham EJ 4th, Faccini L. Social problem-solving deficits and hopelessness, depression, and suicidal risk in college students and psychiatric inpatients. *J Clin Psychol* 1998; **54:** 1091–107.

116 Mynors-Wallis LM, Gath DH, Day A, Baker F. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. *BMJ* 2000; **320:** 26–30.

117 Dowrick C, Dunn G, Ayuso-Mateos JL, et al. Problem solving treatment and group psychoeducation for depression: multicentre randomised controlled trial. Outcomes of Depression International Network (ODIN) Group. *BMJ* 2000; **321:** 1450–4.

118 Barrett JE, Williams JW, Jr., Oxman TE, et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. *J Fam Pract* 2001; **50:** 405–12.

119 Frank E, Rucci P, Katon W, et al. Correlates of remission in primary care patients treated for minor depression. *Gen Hosp Psychiatry* 2002; **24:** 12–19.

120 Wampold BE, Minami T, Baskin TW, Callen Tierney S. A meta-(re)analysis of the effects of cognitive therapy versus 'other therapies' for depression. *J Affect Disord* 2002; **68:** 159–65.

121 APA. Practice guideline for the treatment of patients with major depressive disorder. 2nd edn. Arlington, VA: American Psychiatric Association, 2000.

122 Nutt DJ. Death and dependence: current controversies over the selective serotonin reuptake inhibitors. *J Psychopharmacol* 2003; **17:** 355–64.

123 Walsh MT, Dinan TG. Selective serotonin reuptake inhibitors and violence: a review of the available evidence. *Acta Psychiatr Scand* 2001; **104:** 84–91.

124 Herxheimer A, Mintzes B. Antidepressants and adverse effects in young patients: uncovering the evidence. *CMAJ* 2004; **170:** 487–89.

125 Committee on Energy and Commerce. FDA's role in protecting the public health: examining FDA's review of safety and efficacy concerns in anti-depressant use by children. Hearing before the subcommittee on oversight and investigations of the committee on energy and commerce. Washington, DC: House of Representatives, One Hundred Eighth Congress, Second Session, 2004.

126 Weller IVD, Ashby D, Brook R, et al. Report of the Committee on Safety of Medicines expert working group on the safety of selective serotonin reuptake inhibitor antidepressants. London: Medicines and Healthcare products Regulatory Agency, 2004.

127 Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability. *Lancet* 2001; **358:** 854–56.

128 Fava GA. Conflict of interest in psychopharmacology: can Dr Jekyll still control Mr Hyde? *Psychother Psychosom* 2004; **73:** 1–4.

129 Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. *Lancet* 2004; **363:** 1341–45.

130 Wohlfarth T, Lekkerkerker F, van Zwieten B. Use of selective serotonin reuptake inhibitors in childhood depression. *Lancet* 2004; **364:** 659–60.

131 Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. *Arch Gen Psychiatry* 2005; **62:** 165–72.

132 Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ. Antidepressants and suicide risk in the United States, 1985–1999. *J Clin Psychiatry* 2004; **65:** 1456–62.

133 Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. *BMJ* 2005; **330:** 385.

134 Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. *BMJ* 2005; **330:** 396.

135 Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviours. *JAMA* 2004; **292:** 338–43.

136 Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. *BMJ* 2005; **330:** 389.

137 Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. *Acta Psychiatr Scand* 2005; **111:** 286–90.

138 Yerevanian BI, Koek RJ, Feusner JD, Hwang S, Mintz J. Antidepressants and suicidal behaviour in unipolar depression. *Acta Psychiatr Scand* 2004; **110:** 452–58.

139 Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. *Lancet* 2005; **365:** 482–87.

140 Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. *Int J Neuropsychopharmacol* 2002; **5:** 73–103.

141 Pascual-Leone A, Rubio B, Pallardo F, Catala MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. *Lancet* 1996; **348:** 233–37.

142 George MS, Wassermann EM, Kimbrell TA, et al. Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. *Am J Psychiatry* 1997; **154:** 1752–56.

143 Avery DH, Claypoole K, Robinson L, et al. Repetitive transcranial magnetic stimulation in the treatment of medication-resistant depression: preliminary data. *J Nerv Ment Dis* 1999; **18:** 114–17.

144 Kimbrell TA, Little JT, Dunn RT, et al. Frequency dependence of antidepressant response to left prefrontal repetitive transcranial magnetic stimulation (rTMS) as a function of baseline cerebral glucose metabolism. *Biol Psychiatry* 1999; **46:** 1603–13.

145 Klein E, Kreinin I, Chistyakov A, et al. Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study. *Arch Gen Psychiatry* 1999; **56:** 315–20.

146 Loo C, Mitchell P, Sachdev P, McDarmont B, Parker G, Gandevia S. Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. *Am J Psychiatry* 1999; **156:** 946–48.

147 Padberg F, Zwanzger P, Thoma H, et al. Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. *Psychiatry Res* 1999; **88:** 163–71.

148 Stikhina N, Lyskov EB, Lomarev MP, Aleksanian ZA, Mikhailov VO, Medvedev SV. [Transcranial magnetic stimulation in neurotic depression]. *Zh Nevrol Psikhiatr Im S S Korsakova* 1999; **99:** 26–29.

149 Berman RM, Narasimhan M, Sanacora G, et al. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. *Biol Psychiatry* 2000; **47:** 332–37.

150 Eschweiler GW, Wegerer C, Schlotter W, et al. Left prefrontal activation predicts therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) in major depression. *Psychiatry Res* 2000; **99:** 161–72.

151 George MS, Nahas Z, Molloy M, et al. A controlled trial of daily left prefrontal cortex TMS for treating depression. *Biol Psychiatry* 2000; **48:** 962–70.

152 Garcia-Toro M, Pascual-Leone A, Romera M, et al. Prefrontal repetitive transcranial magnetic stimulation as add on treatment in depression. *J Neurol Neurosurg Psychiatry* 2001; **71:** 546–48.

153 Lisanby SH, Pascual-Leone A, Sampson SM, Boylan LS, Burt T, Sackeim HA. Augmentation of sertraline antidepressant treatment with transcranial magnetic stimulation. *Biol Psychiatry* 2001; **49:** 81S–81S.

154 Manes F, Jorge R, Morcuende M, Yamada T, Paradiso S, Robinson RG. A controlled study of repetitive transcranial magnetic stimulation as a treatment of depression in the elderly. *Int Psychogeriatr* 2001; **13:** 225–31.

155 Boutros NN, Gueorguieva R, Hoffman RE, Oren DA, Feingold A, Berman RM. Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression. *Psychiatry Res* 2002; **113:** 245–54.

156 Padberg F, Zwanzger P, Keck ME, et al. Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. *Neuropsychopharmacology* 2002; **27:** 638–45.

157 Loo CK, Mitchell PB, Croker VM, et al. Double-blind controlled investigation of bilateral prefrontal transcranial magnetic stimulation for the treatment of resistant major depression. *Psychol Med* 2003; **33:** 33–40.

158 Nahas Z, Kozel FA, Li X, Anderson B, George MS. Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy. *Bipolar Disord* 2003; **5:** 40–47.

159 Herwig U, Lampe Y, Juengling FD, et al. Add-on rTMS for treatment of depression: a pilot study using stereotaxic coil-navigation according to PET data. *J Psychiatr Res* 2003; **37:** 267–75.

160 Hoeppner J, Schulz M, Irmisch G, Mau R, Schlafke D, Richter J. Antidepressant efficacy of two different rTMS procedures. High frequency over left versus low frequency over right prefrontal cortex compared with sham stimulation. *Eur Arch Psychiatry Clin Neurosci* 2003; **253:** 103–09.

161 Fitzgerald PB, Brown TL, Marston NA, Daskalakis ZJ, De Castella A, Kulkarni J. Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. *Arch Gen Psychiatry* 2003; **60:** 1002–08.

162 Hausmann A, Kemmler G, Walpoth M, et al. No benefit derived from repetitive transcranial magnetic stimulation in depression: a prospective, single centre, randomised, double blind, sham controlled "add on" trial. *J Neurol Neurosurg Psychiatry* 2004; **75:** 320–02.

163 Jorge RE, Robinson RG, Tateno A, et al. Repetitive transcranial magnetic stimulation as treatment of poststroke depression: a preliminary study. *Biol Psychiatry* 2004; **55:** 398–405.

164 Holtzheimer PE 3rd, Russo J, Claypoole KH, Roy-Byrne P, Avery DH. Shorter duration of depressive episode may predict response to repetitive transcranial magnetic stimulation. *Depress Anxiety* 2004; **19:** 24–30.

165 Kauffmann CD, Cheema MA, Miller BE. Slow right prefrontal transcranial magnetic stimulation as a treatment for medication-resistant depression: a double-blind, placebo-controlled study. *Depress Anxiety* 2004; **19:** 59–62.

166 Mosimann UP, Schmitt W, Greenberg BD, et al. Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients. *Psychiatry Res* 2004; **126:** 123–33.

167 Poulet E, Brunelin J, Boeuve C, et al. Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment. *Eur Psychiatry* 2004; **19:** 382–83.

168 Koerselman F, Laman DM, van Duijn H, van Duijn MA, Willems MA. A 3-month, follow-up, randomized, placebo-controlled study of repetitive transcranial magnetic stimulation in depression. *J Clin Psychiatry* 2004; **65:** 1323–28.

169 Dunlap WP, Cortina JM, Vaslow JB, Burke MJ. Meta-analysis of experiments with matched groups or repeated measures designs. *Psychol Methods* 1996; **1:** 170–77.

170 Shajahan PM, Glabus MF, Steele JD, et al. Left dorso-lateral repetitive transcranial magnetic stimulation affects cortical excitability and functional connectivity, but does not impair cognition in major depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2002; **26:** 945–54.

171 Strafella AP, Paus T, Fraraccio M, Dagher A. Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. *Brain* 2003; **126:** 2609–15.

172 Keck ME, Welt T, Muller MB, et al. Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system. *Neuropharmacology* 2002; **43:** 101–09.

173 Paulus W. Toward establishing a therapeutic window for rTMS by theta burst stimulation. *Neuron* 2005; **45:** 181–83.

174 Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. *Neuron* 2005; **45:** 201–06.

175 Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the safety of repetitive transcranial magnetic stimulation, June 5–7, 1996. *Electroencephalogr Clin Neurophysiol* 1998; **108:** 1–16.

176 Lisanby SH, Luber B, Schlaepfer TE, Sackeim HA. Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. *Neuropsychopharmacology* 2003; **28:** 1852–65.

177 Dwork AJ, Arango V, Underwood M, et al. Absence of histological lesions in primate models of ECT and magnetic seizure therapy. *Am J Psychiatry* 2004; **161:** 576–78.

178 Kosel M, Frick C, Lisanby SH, Fisch HU, Schlaepfer TE. Magnetic seizure therapy improves mood in refractory major depression. *Neuropsychopharmacology* 2003; **28:** 2045–48.

179 Lisanby SH, Moscrip T, Morales O, Luber B, Schroeder C, Sackeim HA. Neurophysiological characterization of magnetic seizure therapy (MST) in non-human primates. *Suppl Clin Neurophysiol* 2003; **56:** 81–99.

180 UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *Lancet* 2003; **361:** 799–808.

181 NICE. Technology appraisal guidance 59: electroconvulsive teatment. technology appraisal guidances. London: National Institute for Clinical Excellence, 2003.

182 Lisanby SH, Maddox JH, Prudic J, Devanand DP, Sackeim HA. The effects of electroconvulsive therapy on memory of autobiographical and public events. *Arch Gen Psychiatry* 2000; **57:** 581–90.

183 Greenberg RM, Kellner CH. Electroconvulsive therapy: a selected review. *Am J Geriatr Psychiatry* 2005; **13:** 268–81.

184 Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. *JAMA* 2001; **285:** 1299–307.

185 Groves DA, Brown VJ. Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects. *Neurosci Biobehav Rev* 2005; **29:** 493–500.

186 Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. *Neuron* 2005; **45:** 651–660.

187 CRAG Working Group. Neurosurgery for mental disorder (J2318 7/96). Edinburgh: HM Stationery Office Scotland, 1996.

188 Nuttin B, Cosyns P, Demeulemeester H, Gybels J, Meyerson B. Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. *Lancet* 1999; **354:** 1526.

189 Sturm V, Lenartz D, Koulousakis A, et al. The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders. *J Chem Neuroanat* 2003; **26:** 293–39.

190 Newcombe R. The lesion in stereotactic subcaudate tractotomy. *Br J Psychiatry* 1975; **126:** 478–81.

191 Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine: how to practice and teach EBM. London: Churchill Livingstone, 1998.

192 Matthews K, Eljamel MS. Status of neurosurgery for mental disorder in Scotland. Selective literature review and overview of current clinical activity. *Br J Psychiatry* 2003; **182:** 404–11.

193 Kringelbach ML, Rolls ET. The functional neuroanatomy of the human orbitofrontal cortex: evidence from neuroimaging and neuropsychology. *Prog Neurobiol* 2004; **72:** 341–72.

194 Damasio AR. Descarte's error: emotion, reason and the human brain. London: Papermac, 1994.

195 Baev KV, Greene KA, Marciano FF, et al. Physiology and pathophysiology of cortico-basal ganglia-thalamocortical loops: theoretical and practical aspects. *Prog Neuropsychopharmacol Biol Psychiatry* 2002; **26:** 771–804.